We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives
KEY MARKETS
Operations in
As an international pharmaceutical company which focuses on local and global markets, Pharmadax’s group operates pharmaceutical business in the following areas:
— Taiwan
— USA
— China and emerging countries
USA – Focused Market
USA being the largest generic market and having management experience in the region, it was the first choice.
Current pipeline is focused on blockbuster opportunities and also riding the second wave launches.
China – The Next Frontier
Generics had shown exponential growth and Pharmadax will leverage its manufacturing location and have initiated filings in the country, take for collaborative approach to push.
MILESTONES
Pharmadax was founded by two Pharma Technocrats, with a core idea of bringing quality pharmaceuticals with efficient technological advantage to the market at a reasonable price. Thus creating a value proposition for each stakeholder. Having successfully founded two companies together, this partnership came naturally.
-
Quetiapine Fumarate ER Tablets was included in the priority review process by CFDA
-
FDA approval and launch of Quetiapine Fumarate ER Tablets in US
-
FDA approval and launch of Glyburide Tablets in US
-
Won the 12th annual Golden Torch Awards of
Enterprise Excellence of R.O.C. -
ANDA Submission: Quetiapine Fumarate ER Tab
-
Plant A passed USFDA inspection, without 483s
Listing on Taiwan Stock Exchange （Ticker Code: 4191） -
FDA approved Levetiracetam ER Tablet
The 2nd GMP plant (Plant B) was established in China
GMP QC Lab was set up in Taipei, Taiwan -
ANDA Submission :
Glyburide Tab & Metoprolol Succinate ER Tab -
First ANDA Submission : Levetiracetam 750, 500mg
ER Tablet ( Keppra® XR ) -
R&D centers were set up in Taipei and China
Plant A got FDA production approval in China -
The GMP plant was set up in China (Plant A)
The headquarter of Pharmadax was established in Taipei